Pharmacogenomic considerations in drug delivery

Pharmacogenomics

Volumn 4, Issue 4, 2003, Pages 443-461

  Attar, Mayssa ^a,b   Lee, Vincent H L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Drug delivery; Enzymes; Interindividual variability; Pharmacodynamics; Pharmacogenomics; Pharmacokinetics; Receptors; Transporters

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 4A; DEBRISOQUINE; DEXTROMETHORPHAN; DIMETHYLANILINE MONOOXYGENASE; DNA TOPOISOMERASE INHIBITOR; DRUG METABOLIZING ENZYME; EPIPODOPHYLLOTOXIN; IMIPRAMINE; IRINOTECAN; MERCAPTOPURINE; NEUROLEPTIC AGENT; PROPRANOLOL; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; SIMVASTATIN; SULFONAMIDE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TROPISETRON; UNINDEXED DRUG;

BLOOD TOXICITY; CIRCULATION; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; VARIANCE; VOMITING;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACOGENETICS;

EID: 0038445929     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.4.443.22749     Document Type: Review

References (79)

1. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 356,1667-1671 (2000).
2. Lindpaintner K: The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1, 463-469 (2002).
3. Liggett SB: Pharmacogenetic applications of the Human Genome project. Nat. Med. 7, 281-283 (2001).
4. Wilkinson GR: Pharmacokinetics. The dynamics of drug absorption, distribution and elimination. In: Goodman and Gilman's: The pharmacological basis of therapeutics. Hardman AJG, Limbird LE (Eds), McGraw-Hill, New York 3-30 (2001).
5. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
6. Ball S, Borman N: Pharmacogenetics and drug metabolism. Nat. Biotech. 16, 4-5 (1998).
7. Ingelman-Sundberg M: Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250, 186-200 (2001).
8. Gerhold D, Lu M, Xu J, Austin C, Caskey CT, Rushmore T: Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol. Genomics 5, 161-170 (2001).
9. Lin JH, Lu AY: Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35, 361-390 (1998).
10. Parkinson A: An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Pathol. 24, 48-57 (1996).
11. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
12. Lin JH, Lu AY: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49, 403-449 (1997).
13. Daly AK: Pharmacogenetics. In: Handbook of Drug Metabolism. Woolf TF (Ed.), Marcel Dekker, Inc., New York, 175-202 (1999).
14. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL: Polymorphic hydroxylation of Debrisoquine in man. Lancet 2, 584-586 (1977).
15. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
16. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90, 11825-11829 (1993).
17. Zanger UM, Fischer J, Raimundo S et al: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585 (2001).
18. Johnson K, Shah A, Jaw-Tsai S, Baxter J, Prakash C: Metabolism, pharmacokinetics and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. Drug Metab. Dispos. 31, 76-87 (2003).
19. Mulder AB, van Lijf HJ, Bon MA et al.: Association of polymorphism in the cytochrome cYP2D6 and the efficacy and tolerability of simvastatin. Clin. Pharmacol. Ther. 70, 546-551 (2001).
20. Kaiser R, Sezer O, A Papies et al.: Patient-tailored antiemetic treatment with 5-hydroxytryptamine Type 3 receptor antagonists according to cytochrome P450 2D6 genotypes. J. Clin. Oncol. 20, 2805-2811 (2002).
21. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2, 25-31 (1992).
22. Furuta T, Ohashi K, Kosuge K et al.: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 65, 552-561 (1999).
23. Shu Y, Wang LS, Xu ZH et al.: 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. J. Pharmacol. Exp. Ther. 295, 844-851 (2000).
24. Ingelman-Sundberg M: Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 181-182, 447-452 (2002).
25. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
26. Wrighton SA, Thummel RH: CYP3A. In: Metabolic Drug Interactions. Levy KE, Thummel KE, Trager WF, Hansten PD, M Eichelbaum (Eds), Lippincott Williams & Wilkins, Philadelphia 115-133 (2000).
27. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumours by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225-1229 (1998).
28. Sata F, Sapone A, Elizondo G et al.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12, evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48-56 (2000).
29. Felix CA, Walker AH, Lange BJ et al.: Association of CYP3A4 genotype with treatment-related leukaemia, Proc. Natl. Acad. Sci. USA 95, 13176-13181 (1998).
30. Ball SE, Scatina J, Kao J et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66, 288-294 (1999).
31. Ruijter E, van de Kaa KC, Miller G, Ruiter D, Debruyne F, Schalken J: Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev. 20, 22-45 (1999).
32. Hsieh KP, Lin YY, Cheng CL et al.: Novel mutations of CYP3A4 in Chinese, Drug Metab. Dispos. 29, 268-273 (2001).
33. DM Ziegler: Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Ann. Rev. Pharmacol. Toxicol. 33, 179-199 (1993).
34. Cashman JR: Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem. Res. Toxicol. 8, 166-181 (1995).
35. Cashman JR, Zhang J: Interindividual differences of human flavin-containing monooxygenase 3, genetic polymorphisms and functional variation. Drug Metab. Dispos. 30, 1043-1052 (2002).
36. Cashman JR, Zhang J, Leushner J, Braun A: Population distribution of human flavin-containing monooxygenase form 3, gene polymorphisms. Drug Metab. Dispos. 29, 1629-1637 (2001).
37. JR Cashman: Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 3, 325-339 (2002).
38. Fei YJ, Kanai Y, Nussberger S et al.: Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 368, 563-566 (1994).
39. McLeod HL, Siva C: The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics. 3, 89-98 (2002).
40. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. USA 92, 949-953 (1995).
41. Tai HL, Krynetski EY, Yates CR et al.: Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 58, 694-702 (1996).
42. Loennechen T, Yates CR, Fessing MY, Relling MV, Krynetski EY, Evans WE: Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin. Pharmacol. Ther. 64, 46-51 (1998).
43. Evans WE, Hon YY, Bomgaars L et al.: Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 19, 2293-2301 (2001).
44. Lee VH, Sporty JL, Fandy TE: Pharmacogenomics of drug transporters: the next drug delivery challenge. Adv. Drug Deliv. Rev. 50(Suppl. 1), S33-S40 (2001).
45. Leveille-Webster CR, Arias IM: The biology of the P-glycoproteins. J. Membr. Biol. 143, 89-102 (1995).
46. RB Kim: Transporters and xenobiotic disposition. Toxicology 181-182, 291-297 (2002).
47. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multi-drug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
48. Siddiqui A, Kerb R, Weale ME et al.: Association of multi-drug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448 (2003).
49. Tanabe M, Ieiri I, Nagata N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multi-drug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297, 1137-1143 (2001).
50. Yamauchi A, Ieiri I, Kataoka Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74, 571-572 (2002).
51. Nozawa T, Nakajima M, Tamai I et al.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804-813 (2002).
52. Konig J, Cui Y, Nies AT, Keppler D: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G156-G164 (2000).
53. Tirona RG, Leake BF. Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
54. Tamai I, Nezu J, Uchino H et al.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273, 251-260 (2000).
55. Leabman MK, Huang CC, Kawamoto M et al.: Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12, 395-405 (2002).
56. Dresser MJ, Leabman MK, Giacomini KM: Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. 90, 397-421 (2001).
57. Insel PA: Seminars in medicine of the Beth Israel Hospital, Boston: Adrenergic receptors-evolving concepts and clinical implications. N. Engl. J. Med. 334, 580-585 (1996).
58. Hoffman BB, Taylor JG: Neurotransmission. The autonomic and somatic motor nervous systems. In: Goodman and Gilman's: The Pharmacological Basis of Therapeutics. Hardman AJG, Limbird LE (Eds), McGraw-Hill, New York, 115-153 (2001).
59. Drysdale CM, McGraw DW, Stack CB et al.: Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA 97, 10483-10488 (2000).
60. Dishy V, Sofowora GG, Xie HG et al.: The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030-1035 (2001).
61. Hoffman BB: Catecholamine, sympathomimetic drugs and adrenergic receptor antagonists. In: Goodman and Gilman's: The Pharmacological Basis of Therapeutics. Hardman AJG, Limbird LE (Eds), McGraw-Hill, New York, 269-290 (2001).
62. Cavalli A, Lattion AL, Hummler E et al.: Decreased blood pressure response in mice deficient of the α1b-adrenergic receptor. Proc. Natl. Acad. Sci. USA 94, 11589-11594 (1997).
63. Ramarao CS, Denker JM, Perez DM, Gaivin RJ, Riek RP, Graham RM: Genomic organization and expression of the human α1B-adrenergic receptor. J. Biol. Chem. 267, 21936-21945 (1992).
64. Buscher R, Herrmann V, Ring KM et al.: Variability in phenylephrine response and essential hypertension: a search for human α(1b)-adrenergic receptor polymorphisms. J. Pharmacol. Exp. Ther. 291, 793-798 (1999).
65. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol. 38, 97-120 (1998).
66. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA: Functional characterization of cyclooxygenase-2 polymorphisms. J. Pharmacol. Exp. Ther. 299, 468-476 (2001).
67. Klabe RM, Bacheler LT, Ala PJ, Erickson-Viitanen S, Meek JL: Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 37, 8735-8742 (1998).
68. Velazquez-Campoy A, Todd MJ, Vega S, Freire E: Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc. Natl. Acad. Sci. USA 98, 6062-6067 (2001).
69. Velazquez-Campoy A, Vega S, Freire E: Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 41, 8613-8619 (2002).
70. Herve F, Duche JC, d'Athis P et al.: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics 6, 403-415 (1996).
71. Jolliet-Riant P, Boukef MF, Duche JC, Simon N, Tillement JP: The genetic variant A of human α 1-acid glycoprotein limits the blood to brain transfer of drugs it binds. Life Sci. 62, L219-L226 (1998 ).
72. Taheri S, Cogswell LP, III, Gent A, Strichartz GR: Hydrophobic and ionic factors in the binding of local anesthetics to the major variant of human alpha1-acid glycoprotein. J. Pharmacol. Exp. Ther. 304, 71-80 (2003).
73. Benet LZ, Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71, 115-121 (2002).
74. Willson TM, Kliewer SA: PXR, CAR and drug metabolism, Nat. Rev. Drug Discov. 1, 259-266 (2002).
75. Chang TK, Bandiera SM, Chen JX: Constitutive androstane receptor and pregnane receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos. 31, 7-10 (2003).
76. Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets and side effects. N. Engl. J. Med. 348, 538-549 (2003).
77. KA Phillips A US, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).
78. de Vries EM, Pot HJ, Conemans JMH, Uges DRA: The clinical relevance of routine genotyping of CYP2D6/2C19 null alleles of psychiatric patients. Br. J. Clin. Pharmacol. 53, 550P-551P (2002).
79. Issa AM: Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat. Rev. Drug Discov. 1, 300-308 (2002).